INDIA – Bharat Serums and Vaccines (BSV) has acquired Tidilan (Isoxsuprine hydrochloride), a brand in women’s health, from Jagdale Industries, according to a statement issued by BSV.

However, BSV did not disclose the financial details of the acquisition or the Tidilan’s annual sales.

Tidilan is currently available in tablet and injectable dosage forms, according to the company. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, AntiD, among others.

For over five decades, BSV has developed a range of biological, biotech, and pharmaceutical products for women’s health, infertility (Intrauterine insemination/In-vitro fertilization), and critical, and emergency care.

Tidilan is a drug that is used to relax uterine muscles in order to prevent premature labor in pregnant women.

It is a ‘vasodilator’ medication that is used to treat and prevent Raynaud’s phenomenon, cerebral vascular insufficiency (arteriosclerosis), and other conditions involving poor blood flow in blood vessels (veins and arteries), according to the statement.

Speaking about this, Sanjiv Navangul, managing director & CEO, Bharat Serums & Vaccines said, “There exists a lot of opportunity in India to address the medical needs of women.  As a focused women’s health company, we are committed to acquiring brands that complement our current women’s portfolio.

We are delighted with the addition of Tidilan (Isoxsuprine hydrochloride) to BSV’s Women’s Healthcare portfolio. This will be an important milestone towards our goal of being the top three women’s health players in India and as we continue to bring treatments and cures that help serve our patients better.”

Rajesh Jagdale, chairman & managing director, Jagdale Industries, added, “We are committed to delivering excellence through quality and innovation.

We are proud of our market leading brand, Tidilan (Isoxsuprine hydrochloride) and are delighted with this partnership with BSV as we are confident that this will expand BSV’s offerings in women’s health as they work towards bringing more products that will improve lives of women in the country.”

Backed by Advent, BSV is looking to strengthen its women health portfolio. The company last month agreed to buy TKK Healthcare’s pharma business for Rs 805 crore (US$106.5 million), which gives it access to the latter’s key women health brands.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE